International Journal of Hematology最新文献_第6页

Iron deficiency and phlebotomy in patients with polycythemia vera. 红细胞增多症患者的铁缺乏症和抽血疗法。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-11 DOI: 10.1007/s12185-024-03868-z

Yoko Edahiro, Norio Komatsu

引用次数: 0

Factor X consumption attenuates the coagulation effect of emicizumab: a case of severe hemophilia A treated with emicizumab and factor VIII-bypassing agents. 因子 X 消耗减弱了埃米珠单抗的凝血作用：一例使用埃米珠单抗和因子 VIII 旁路药物治疗的严重 A 型血友病患者。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-01 Epub Date: 2024-10-30 DOI: 10.1007/s12185-024-03860-7

Kuniyoshi Mizumachi, Kenichi Ogiwara, Yuto Nakajima, Naruto Shimonishi, Shoko Furukawa, Masahiro Takeyama, Keiji Nogami

{"title":"Factor X consumption attenuates the coagulation effect of emicizumab: a case of severe hemophilia A treated with emicizumab and factor VIII-bypassing agents.","authors":"Kuniyoshi Mizumachi, Kenichi Ogiwara, Yuto Nakajima, Naruto Shimonishi, Shoko Furukawa, Masahiro Takeyama, Keiji Nogami","doi":"10.1007/s12185-024-03860-7","DOIUrl":"10.1007/s12185-024-03860-7","url":null,"abstract":"In patients with hemophilia A with inhibitor (PwHA-I), emicizumab drastically reduces bleeding events. However, few studies have investigated the behavior and effects of factor X (FX) in patients who require intensive treatment with factor VIII-bypassing agents (BPA) and emicizumab. A 59-year-old man with HA-I receiving emicizumab prophylaxis was admitted to our hospital because of acute gangrenous cholecystitis. He received percutaneous transhepatic gallbladder drainage and laparoscopic cholecystectomy along with repeated administration of recombinant activated factor VII (rFVIIa). On day 10, a large hematoma developed around the residual gallbladder. Rotational thromboelastometry (ROTEM) suggested poor effect of rFVIIa and reduced activity of emicizumab. Considering that this could be due to consumption of FX, plasma-derived FVIIa/FX agent (pdFVIIa/X) was administered, and ROTEM parameters recovered considerably. The patient was discharged on day 19 uneventfully. Plasma assays revealed that FX antigen level (FX:Ag) was 107.5% at baseline but then decreased. Administration of pdFVIIa/FX restored FX:Ag (pre/post 47.2%/125.5%). ROTEM and thrombin generation assay with in vitro addition of anti-emicizumab antibody suggested that low FX:Ag was responsible for attenuating the effect of emicizumab, and pdFVIIa/FX administration restored coagulation potentials. In PwHA-I receiving intensive treatment with rFVIIa under emicizumab prophylaxis, FX consumption might attenuate the effect of emicizumab.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"126-130"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between early anti-cytomegalovirus therapy and the incidence of chronic graft-versus-host disease. 早期抗巨细胞病毒治疗与慢性移植物抗宿主疾病发病率之间的关系。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-14 DOI: 10.1007/s12185-024-03871-4

Kotaro Miyao, Makoto Murata, Tetsuya Nishida, Yukiyasu Ozawa, Naoyuki Uchida, Takahiro Fukuda, Noriko Doki, Tetsuya Eto, Toshiro Kawakita, Yasuo Mori, Satoru Takada, Hiroyuki Ohigashi, Masatsugu Tanaka, Yoshinobu Kanda, Ken-Ichi Matsuoka, Fumihiko Ishimaru, Yoshiko Atsuta, Junya Kanda, Seitaro Terakura

{"title":"Association between early anti-cytomegalovirus therapy and the incidence of chronic graft-versus-host disease.","authors":"Kotaro Miyao, Makoto Murata, Tetsuya Nishida, Yukiyasu Ozawa, Naoyuki Uchida, Takahiro Fukuda, Noriko Doki, Tetsuya Eto, Toshiro Kawakita, Yasuo Mori, Satoru Takada, Hiroyuki Ohigashi, Masatsugu Tanaka, Yoshinobu Kanda, Ken-Ichi Matsuoka, Fumihiko Ishimaru, Yoshiko Atsuta, Junya Kanda, Seitaro Terakura","doi":"10.1007/s12185-024-03871-4","DOIUrl":"10.1007/s12185-024-03871-4","url":null,"abstract":"Ganciclovir and foscarnet are two representative anti-cytomegalovirus (CMV) agents. A previous regional study revealed a lower risk of chronic graft-versus-host disease (GVHD) in patients who received pre-emptive foscarnet. We conducted a retrospective nationwide study to confirm the results. A total of 8890 patients aged 16 or older with hematological malignancies who received foscarnet (n = 1555) or ganciclovir (n = 7335) during their first hematopoietic stem cell transplantation (HSCT) were included. The risks of chronic GVHD (hazard ratio [HR], 1.26; 95% confidence interval [CI], 1.13-1.40; P < 0.001) and extensive chronic GVHD (HR, 1.16; 95% CI, 1.01-1.33; P = 0.033) were higher with ganciclovir. Among male patients with a female donor, the incidence of extensive chronic GVHD 3 years after HSCT was clearly lower with foscarnet (13%; 95% CI, 9-16%) than with ganciclovir (27%; 95% CI, 25-29%; P < 0.001). In male patients who received HSCT from female donors, foscarnet recipients showed significantly lower incidence of extensive chronic GVHD than ganciclovir recipients, regardless of donor source or previous acute GVHD. While caution is necessary, these results indicate that foscarnet affects alloimmunization and might reduce the incidence of chronic GVHD.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"110-125"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia. 吉特替尼联合化疗治疗亚洲新确诊急性髓细胞白血病患者的1/2期研究。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-06 DOI: 10.1007/s12185-024-03840-x

Masashi Sawa, Toshihiro Miyamoto, Hee-Je Kim, Yasushi Hiramatsu, June-Won Cheong, Takayuki Ikezoe, Tomoki Naoe, Koichi Akashi, Satoshi Morita, Masanori Kosako, Moyu Ikegaya, Wataru Terada, Takeshi Kadokura, Jason Hill, Shuichi Miyawaki, Stanley C Gill, Alexandra Heinloth, Nahla Hasabou

{"title":"A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia.","authors":"Masashi Sawa, Toshihiro Miyamoto, Hee-Je Kim, Yasushi Hiramatsu, June-Won Cheong, Takayuki Ikezoe, Tomoki Naoe, Koichi Akashi, Satoshi Morita, Masanori Kosako, Moyu Ikegaya, Wataru Terada, Takeshi Kadokura, Jason Hill, Shuichi Miyawaki, Stanley C Gill, Alexandra Heinloth, Nahla Hasabou","doi":"10.1007/s12185-024-03840-x","DOIUrl":"10.1007/s12185-024-03840-x","url":null,"abstract":"Objective: This interim analysis of a phase 1/2, open-label, single-arm study assessed the safety, efficacy, and pharmacokinetics of gilteritinib plus chemotherapy in adults with newly diagnosed FLT3 mutation-positive acute myeloid leukemia.Methods: In sequential phase 1 and 2 studies, induction and consolidation therapy with gilteritinib 120 mg/day plus chemotherapy (induction: idarubicin/cytarabine once daily; consolidation: cytarabine twice daily) was followed by maintenance gilteritinib 120 mg/day monotherapy. Endpoints included maximum tolerated dose (MTD), recommended expansion dose (RED), and dose-limiting toxicity (phase 1), and complete remission (CR) rate following induction therapy (primary endpoint), overall survival (OS), safety, and pharmacokinetics (phase 2).Results: In phase 1, MTD was not reached and RED was 120 mg/day. In phase 2, the CR rate was 50.0% after induction (90% confidence interval [CI] 40.4, 59.6); however, the lower confidence limit did not exceed the pre-defined 55% benchmark. Composite CR (CRc) rates were high following induction (86.6%, 95% CI [77.3, 93.1]), consolidation, and maintenance therapy (87.8%, 95% CI [78.7, 94.0], each). The probability of OS was 86.6% at 12 months. No new safety findings were reported.Conclusion: In this interim analysis, gilteritinib 120 mg/day in combination with chemotherapy was well tolerated, with similar CRc rates to previous studies.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"56-67"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia. Quizartinib联合供体淋巴细胞输注治疗FLT3-ITD阳性急性髓性白血病移植后复发。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-01 Epub Date: 2024-10-26 DOI: 10.1007/s12185-024-03863-4

Fumihiko Ouchi, Naoki Shingai, Yuho Najima, Daichi Sadato, Chizuko Hirama, Satoshi Wakita, Kaori Kondo, Yasutaka Sadaga, Chika Kato, Satoshi Sakai, Yasuhiro Kambara, Masashi Shimabukuro, Kazuki Inai, Takashi Toya, Hiroaki Shimizu, Kyoko Haraguchi, Takeshi Kobayashi, Hironori Harada, Yoshiki Okuyama, Hiroki Yamaguchi, Yuka Harada, Noriko Doki

{"title":"Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia.","authors":"Fumihiko Ouchi, Naoki Shingai, Yuho Najima, Daichi Sadato, Chizuko Hirama, Satoshi Wakita, Kaori Kondo, Yasutaka Sadaga, Chika Kato, Satoshi Sakai, Yasuhiro Kambara, Masashi Shimabukuro, Kazuki Inai, Takashi Toya, Hiroaki Shimizu, Kyoko Haraguchi, Takeshi Kobayashi, Hironori Harada, Yoshiki Okuyama, Hiroki Yamaguchi, Yuka Harada, Noriko Doki","doi":"10.1007/s12185-024-03863-4","DOIUrl":"10.1007/s12185-024-03863-4","url":null,"abstract":"FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive acute myeloid leukemia (AML) has a poor prognosis, particularly with DNMT3A and NPM1 mutations. Quizartinib, a FLT3 inhibitor showing clinical benefit in FLT3-ITD-positive AML, has unclear safety and efficacy when combined with donor lymphocyte infusion (DLI). We report a case of FLT3-ITD-positive AML with DNMT3A and NPM1 mutations that relapsed after allogeneic hematopoietic stem cell transplantation (allo-HCT) and was treated with quizartinib and DLI. A 49-year-old man was diagnosed with AML. Target-sequencing analysis of the bone marrow revealed FLT3-ITD, DNMT3A R882, and NPM1 mutations. Although the patient achieved complete remission (CR) through induction therapy and received allo-HCT, he relapsed on day 71. Quizartinib was initiated on day 79, and the patient achieved CR with incomplete recovery on day 106. He did not desire a second allo-HCT and continued quizartinib in combination with DLI, which was started on day 156 and administered eight times every 2 to 3 months. The patient achieved hematological CR on day 163 and remained in molecular CR 3 years after allo-HCT without adverse effects. Quizartinib combined with DLI may be a feasible treatment for early relapse of FLT3-ITD-positive AML after allo-HCT, even with concurrent DNMT3A and NPM1 mutations.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"137-143"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful complete remission after induction therapy with CPX-351 for acute myeloid leukemia with myelodysplasia-related changes accompanied by double-minute chromosomes and MYC gene amplification. 用 CPX-351 诱导治疗伴有双 minute 染色体和 MYC 基因扩增的骨髓增生异常相关病变的急性髓性白血病，成功实现完全缓解。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-11 DOI: 10.1007/s12185-024-03876-z

Masuho Saburi, Takumi Nishikawa, Katsuya Kawano, Eiichi Ohtsuka

引用次数: 0

Safety and efficacy of automatic subcutaneous injection of daratumumab via an infusion pump. 通过输液泵自动皮下注射达拉单抗的安全性和有效性。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-23 DOI: 10.1007/s12185-024-03885-y

Kazuhito Suzuki, Riku Nagao, Tadahiro Gunji, Masaharu Kawashima, Hideki Uryu, Mika Terada, Kayo Namiki, Kaichi Nishiwaki, Shingo Yano

引用次数: 0

JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN). 2023年JSH血液恶性肿瘤实用指南：白血病-4。慢性髓性白血病（CML）/骨髓增生性肿瘤（MPN）。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-26 DOI: 10.1007/s12185-024-03865-2

Naoto Takahashi, Katsuto Takenaka, Noriyoshi Iriyama, Keita Kirito, Tatsuya Kawaguchi, Shinya Kimura, Kazuya Shimoda

引用次数: 0

The in vitro cross-reactivity and blood coagulation potential of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A. 重组猪因子 VIII 在日本获得性血友病 A 患者中的体外交叉反应性和血液凝固潜能。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-01 Epub Date: 2024-10-30 DOI: 10.1007/s12185-024-03854-5

Masahiro Takeyama, Kana Sasai, Yasuo Miyaguchi, Kenichi Ogiwara, Shoko Furukawa, Naruto Shimonishi, Yuto Nakajima, Hitoshi Ueda, Keiji Nogami

{"title":"The in vitro cross-reactivity and blood coagulation potential of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A.","authors":"Masahiro Takeyama, Kana Sasai, Yasuo Miyaguchi, Kenichi Ogiwara, Shoko Furukawa, Naruto Shimonishi, Yuto Nakajima, Hitoshi Ueda, Keiji Nogami","doi":"10.1007/s12185-024-03854-5","DOIUrl":"10.1007/s12185-024-03854-5","url":null,"abstract":"Recombinant porcine factor VIII (rpFVIII) is a hemostatic agent for acquired hemophilia A (AHA). Cross-reaction of auto-antibodies against rpFVIII has been reported, although no data are available in Japanese patients. This study investigated the cross-reactivity and coagulation potential of rpFVIII in plasma samples from Japanese patients with AHA. Cross-reactivity was calculated as the ratio of anti-porcine FVIII inhibitor titer (pFVIII-INH) to human FVIII inhibitor titer. Comprehensive coagulation potential was assessed by clot waveform analysis (CWA) and thrombin generation assay (TGA) in samples spiked with rpFVIII (equivalent to 200 U/kg). Nine of 16 plasma samples (56.3%) had positive pFVIII-INH, with a median cross-reactivity of 1.2%. FVIII activity (FVIII:C) was restored to > 100% in all samples upon spiking with rpFVIII, but was weakly correlated with pFVIII-INH. CWA parameters and most TGA parameters were restored to normal upon spiking with rpFVIII; correlation of these parameters with FVIII:C was similar to that observed in controls. Overall, cross-reactivity to rpFVIII in Japanese patients was similar to that reported in Caucasian patients. Our results suggest that an initial clinical dose of 200 U/kg rpFVIII could restore coagulation potential to normal, and that FVIII:C monitoring after rpFVIII administration may be more informative than pFVIII-INH before administration.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"45-55"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11742282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neoplastic plasma cells demonstrating phagocytosis and clasmatosis. 肿瘤性浆细胞表现出吞噬和凝集功能。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-04 DOI: 10.1007/s12185-024-03870-5

Radu Chiriac

引用次数: 0